PharmaCote EC is the latest addition to I Holland?s comprehensive range of tool coatings. It is an excellent general purpose coating capable of addressing a combination of production issues such as sticking, corrosion and wear.
PharmaCote EC is the latest addition to I Holland’s comprehensive range of tool coatings. It is an excellent general purpose coating capable of addressing a combination of production issues such as sticking, corrosion and wear. It is also a great alternative to traditional hard chromium coatings over which corrosion resistance, wear resistance and anti-stick properties are all improved. As with all PharmaCote coatings, tool care is very straight forward using an ultrasonic bath followed by light automated polishing. PharmaCote EC is available as an all over coating, or is applied to the tip and barrel only.Other coatings in the PharmaCote range include PharmaCote HC & HC+ (Hard Chromium) for general corrosion and wear resistance; PharmaCote CN and CN+ (Chromium Nitride) for a premium anti-stick solution; PharmaCote TN (Titanium Nitride) for general purpose wear resistance; PharmaCote RS (Resilient Surface) for a premium anti-abrasion solution; and PharmaCote DN (Dymonic) for general purpose anti-stick, anti-corrosion and anti-wear characteristics.
For further information on PharmaCote EC and other coatings in the Holland PharmaCote range, please contact: info@iholland.co.uk or visit www.iholland.co.uk where you can find the latest PharmaCote brochure.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.